Welcome to our dedicated page for Veracyte news (Ticker: VCYT), a resource for investors and traders seeking the latest updates and insights on Veracyte stock.
Veracyte, Inc. (Nasdaq: VCYT) is a global cancer diagnostics and genomic testing company whose news flow centers on clinical evidence, test performance, and financial results. The company describes its mission as transforming cancer care by empowering clinicians with high-value insights at key decision points in diagnosis and treatment. Its Veracyte Diagnostics Platform underpins tests such as Decipher Prostate, Afirma GSC, Prosigna, Decipher Bladder, and the Percepta Nasal Swab test, along with research tools like Afirma GRID and Decipher GRID.
On this page, readers can follow Veracyte news related to quarterly and annual financial results, including revenue and testing volume updates the company announces in earnings press releases and accompanying conference calls. Veracyte’s communications also highlight non-GAAP measures such as adjusted EBITDA and adjusted EBITDA margin, along with explanations of how these metrics are used internally and how they differ from GAAP figures.
Another major category of news involves clinical and scientific developments. Veracyte regularly reports on studies and abstracts that use its Afirma GRID and Decipher GRID platforms to develop and evaluate molecular signatures in thyroid and prostate cancer. Examples include publications on Afirma GRID-derived signatures to differentiate thyroid cancer risk groups and prospective validation data for biomarkers such as the PAM50 molecular signature in recurrent prostate cancer.
Investors and clinicians can also find announcements about Veracyte’s participation in healthcare and investor conferences, where management presents updates on the company’s diagnostics portfolio, research programs, and financial outlook. For ongoing insight into how Veracyte’s genomic tests and research tools are being used in practice and studied in trials, this news feed aggregates the company’s press releases and related updates in one place.
Veracyte (Nasdaq: VCYT) announced significant findings from the PROCURE study, presented at the ESMO Breast Cancer 2022 event in Berlin. The study, which involved 133 oncologists across 11 European countries, reveals that gene expression profile (GEP) testing is crucial for guiding treatment in early-stage breast cancer patients. Key findings include 88% of oncologists valuing GEP results for chemotherapy decisions in node-negative cases, and 75% considering it important for patients with 1 to 3 positive lymph nodes. The data suggests that GEP tests are becoming standard care in Europe.
Veracyte reported impressive first quarter 2022 results, with total revenue soaring by 85% to $67.8 million. Testing revenue reached $56.0 million, a 69% increase driven by the Decipher urology portfolio. Net loss improved by 65% to $14.5 million, corresponding to a $0.20 loss per share, a 70% enhancement year-over-year. The company anticipates total revenue for 2022 to range between $265 million and $275 million, indicating 21% to 25% growth compared to 2021. Cash and cash equivalents stood at $163.6 million.
Veracyte, Inc. (Nasdaq: VCYT) highlights the clinical importance of its Envisia Genomic Classifier for diagnosing idiopathic pulmonary fibrosis (IPF) following an updated practice guideline published in the American Journal of Respiratory and Critical Care Medicine. The guideline emphasizes the test's ability to identify a genomic pattern associated with usual interstitial pneumonia (UIP) without invasive procedures. The Envisia classifier boasts a specificity of 92% and sensitivity of 68%. A significant number of guideline authors advocate for its adoption in clinical settings, which could enhance diagnostic confidence for healthcare professionals.
Veracyte, Inc. (Nasdaq: VCYT) announced that three abstracts showcasing new genomic data on prostate and bladder cancers will be presented at the American Urological Association Annual Meeting from May 13-16, 2022, in New Orleans. These findings are sourced from the Decipher GRID database, encompassing over 100,000 transcriptomes. The data aims to enhance personalized cancer therapies, emphasizing the database's significance for urologic oncology research globally.
Veracyte (Nasdaq: VCYT) announced that new data showcasing its non-invasive Percepta Nasal Swab test for assessing lung cancer risk will be presented at the American Thoracic Society (ATS) 2022 International Conference from May 13-18, 2022, in San Francisco. The test evaluates lung nodules in current and former smokers, potentially reducing unnecessary invasive procedures. The performance of the test has been validated, and it is being provided at select sites while further clinical utility evidence is developed.
Veracyte, Inc. (Nasdaq: VCYT) will release its financial results for Q1 2022 on May 3, 2022, after market close. The management will host a conference call at 4:30 p.m. ET to discuss results and provide a business update. U.S. participants can dial (855) 541-0980, while international participants can call (970) 315-0440, using Conference ID 3848138. The call will be webcast live on the company's website, with a replay available later. Veracyte specializes in diagnostic tests that enhance patient care and reduce unnecessary procedures.
Veracyte (Nasdaq: VCYT) announced its participation in Cowen’s 42nd Annual Health Care Conference on March 8, at 12:50 p.m. Eastern Time. CEO Marc Stapley and CFO Rebecca Chambers will present, with a live audio webcast available on Veracyte’s website. A replay will be accessible for 90 days post-event.
Veracyte is a global diagnostics company focused on improving patient care through advanced diagnostic tests that address prevalent cancers, reducing unnecessary procedures and time to treatment.
Veracyte reported significant growth in Q4 2021, achieving $67.3 million in revenue, a 95% increase year-over-year. For the full year, total revenue reached $219.5 million, up 87%. However, operating expenses rose 104% to $227.0 million, primarily due to acquisition-related costs, leading to a net loss of $75.6 million, a 116% increase. The company anticipates 2022 revenue to be between $260 million and $275 million, marking a growth of 18% to 25%.
Veracyte, Inc. has appointed Annie McGuire as senior vice president and general counsel, effective immediately. McGuire, with extensive experience from Fortune 100 and healthcare companies, will manage the company's legal functions and report directly to CEO Marc Stapley. Previously, she was general counsel at Rakuten Medical and has held leadership positions at MyoKardia, where she played a key role in its $13 billion acquisition by Bristol Myers Squibb. Her appointment is anticipated to enhance Veracyte's strategic vision in diagnostics.
Veracyte, Inc. has appointed Jonathan Wygant as its new chief accounting officer, effective immediately. Wygant will manage all global accounting operations, financial reporting, and tax functions, reporting directly to Rebecca Chambers, the CFO. He previously held finance leadership roles at several healthcare companies, including as corporate controller at Biosplice Therapeutics. This leadership change aims to strengthen Veracyte's accounting operations as the company pursues its global strategic vision.